A Risk-Benefit Assessment of Epoetin in the Management of Anaemia Associated with Cancer

ISSN： 0114-5916

Source： Drug Safety, Vol.19, Iss.4, 1998-10, pp. : 269-282

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of Abciximab in Angioplasty

By Kleiman N.S.

Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. : 43-57

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Amifostine in Cytoprotection

By Mabro M.

Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. : 367-387

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Antileukotrienes in Asthma

By Smith L.J.

Drug Safety, Vol. 19, Iss. 3, 1998-09 ,pp. : 205-218

Adis International

Access to resources Recommend Favorite

The use of darbepoetin-α to treat anaemia in patients with cancer is associated with lower overall costs compared with epoetin-α and epoetin-β

Inpharma, Vol. 1, Iss. 1562, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Oxytocics in Obstetric Practice

By Winkler M. Rath W.

Drug Safety, Vol. 20, Iss. 4, 1999-04 ,pp. : 323-345

Adis International

Access to resources Recommend Favorite